Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

BACKGROUND: Diroximel fumarate (DRF) is a novel oral fumarate for patients with relapsing–remitting multiple sclerosis (RRMS). DRF and the approved drug dimethyl fumarate yield bioequivalent exposure to the active metabolite monomethyl fumarate; thus, efficacy/safety profiles are expected to be simi...

Descripción completa

Detalles Bibliográficos
Autores principales: Naismith, Robert T, Wolinsky, Jerry S, Wundes, Annette, LaGanke, Christopher, Arnold, Douglas L, Obradovic, Dragana, Freedman, Mark S, Gudesblatt, Mark, Ziemssen, Tjalf, Kandinov, Boris, Bidollari, Ilda, Lopez-Bresnahan, Maria, Nangia, Narinder, Rezendes, David, Yang, Lili, Chen, Hailu, Liu, Shifang, Hanna, Jerome, Miller, Catherine, Leigh-Pemberton, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604551/
https://www.ncbi.nlm.nih.gov/pubmed/31680631
http://dx.doi.org/10.1177/1352458519881761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604551/
https://www.ncbi.nlm.nih.gov/pubmed/31680631
http://dx.doi.org/10.1177/1352458519881761

Ejemplares similares